(WO/1999/051243) THE USE OF ESTRADIOL DERIVATIVES FOR TREATING SIDE-EFFECTS DURING AND/OR AFTER GnRHa THERAPY

(WO/1999/051243) THE USE OF ESTRADIOL DERIVATIVES FOR TREATING SIDE-EFFECTS DURING AND/OR AFTER GnRHa THERAPY

Latest bibliographic data on file with the International Bureau
Pub. No.:  WO/1999/051243   International Application No.:  PCT/DE1999/000355
Publication Date:14.10.1999 International Filing Date:10.02.1999
Chapter 2 Demand Filed: 18.10.1999
IPC: A61K 38/09 (2006.01)
Applicant:JENAPHARM GMBH & CO. KG [DE/DE]; Otto-Schott-Strasse 15, D-07745 Jena (DE).
Inventors:WILDT, Ludwig; (DE).
NEUWINGER, Joachim; (DE).
LICHT, Peter; (DE).
DITTRICH, Ralph; (DE).
OETTEL, Michael; (DE).
HUMMEL, Wolfgang; (DE).
Agent:CRAMER, Eva-Maria; Jenapharm GmbH & Co. KG, Otto-Schott-Strasse 15, D-07745 Jena (DE).
Priority Data:
198 15 060.1 03.04.1998 DE
Title:

(EN) THE USE OF ESTRADIOL DERIVATIVES FOR TREATING SIDE-EFFECTS DURING AND/OR AFTER GnRHa THERAPY

(DE) PHARMAZEUTISCHE PRÄPARATE ZUR THERAPIE VON NEBENWIRKUNGEN WÄHREND UND/ODER NACH EINER GnRHa-THERAPIE

Abstract:

(EN) The invention relates to the use of at least one active agent from the following group: 17$g(a)-estradiol, its chemically modified derivatives and chemically modified derivatives of 17$g(b)-estradiol or estriol; for producing pharmaceutical preparations for treating side effects such as hot flushes during and/or after a treatment with analogs or antagonists of the gonadotropin-releasing hormone (GnRHa-therapy). Said pharmaceutical preparations can be produced in oral and parenteral, including topical, rectal, sub-cutaneous, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal or sub-lingual forms of administration.

(DE) Die vorliegende Erfindung betrifft die Verwendung von mindestens einem Wirkstoff aus der Gruppe 17$g(a)-Estradiol, dessen chemisch modifizierte Derivate, chemisch modifizierte Derivate des 17$g(b)-Estradiol oder des Estriol zur Herstellung pharmazeutischer Präparate zur Therapie von Nebenwirkungen, wie Hitzewallungen, während und/oder nach einer Behandlung mit Analoga oder Antagonisten des Gonadotropin-Releasinghormons (GnRHa-Therapie). Die pharmazeutischen Präparate können als orale und parenterale, incl. als topische, rektale, subcutane, intravenöse, intramuskuläre, intraperitoneale, intranasale, intravaginale, intrabukkale oder sublinguale Applikationsform vorliegen.

Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW.
African Regional Intellectual Property Org. (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language:German (DE)
Filing Language:German (DE)

PATENTSCOPE®

Related Links

E-Newsletters